Calendar

Jan
10
Thu
This enduring activity is focused on use of biologics and targeted therapies in the management of Melanoma.
Jan 10 2019 @ 2:18 pm – Jan 10 2020 @ 3:18 pm

Nursing Management of Patients with Malignant Melanoma

VIEW ACTIVITY

FACULTY
Kathy Madden, RN, MSN, FNP-BC, AOCNP, APHN
NYU Melanoma Program I Clinical Cancer Center
New York, NY

PROGRAM OVERVIEW
This enduring activity is focused on use of biologics and targeted therapies in the management of Melanoma.

TARGET AUDIENCE
This initiative is designed to meet the educational needs of oncologists and oncology nurses involved in the management of patients with Melanoma.

LEARNING OBJECTIVES
Upon completion of this enduring activity, participants will be able to:

Describe the factors contributing to underdiagnoses/misdiagnosis/late diagnosis of melanoma in addition to the underlying pathogenesis and associated cellular pathways that drive metastatic melanoma
Discuss the mechanism of action of available immunotherapies for the treatment of advanced melanoma
Review current clinical trial data for immunotherapy agents in the treatment of un-resectable and metastatic melanoma
Review strategies for recognizing and managing immune-based therapy related toxicities and discuss proper methodologies to relay these strategies
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of oncology patients.
Credits: 1 ANCC Contact Hour(s)

ACCREDITATION STATEMENT:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded a maximum of 1 contact hour(s) of continuing nursing education of RNs and APNs.

ONCC RECERTIFICATION POINTS
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST
Ms. Madden sits on the advisory nursing board for Merck.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Ana Goffin, MPA, Program Manager for Med Learning Group has nothing to disclose.
Nina Oshiokpekhai MS, PharmD, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.

DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture Dr. Madden may mention the use of medications for both FDA-approved and non-approved indications.

DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: January 10, 2019

EXPIRATION DATE: January 10, 2020

VIEW ACTIVITY

This enduring activity is focused on use of biologics and targeted therapies in the management of breast cancer.
Jan 10 2019 @ 2:32 pm – Jan 10 2020 @ 3:32 pm

The Unique Role of the Oncology Nurse in the Targeted Treatment Era of Breast Cancer

VIEW ACTIVITY

FACULTY
Marilyn Douglas, MSN, FNP-BC, OCN
Director of Advanced Practice, Oncology
Laura and Isaac Perlmutter Cancer Center
New York, NY

PROGRAM OVERVIEW
This enduring activity is focused on use of biologics and targeted therapies in the management of breast cancer.

TARGET AUDIENCE
This initiative is designed to meet the educational needs of oncologists and oncology nurses involved in the management of patients with breast cancer.

LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to:

Describe the antitumorigenic mechanisms of the CDK 4/6 inhibitors in hormone receptor-positive breast cancer
Discuss the CDK 4/6 inhibitor clinical trial data for patients with HR+, HER-2 negative advanced breast cancer across multiple lines of therapy
Review the oncology nurses roles in the recognition of breast cancer treatment related adverse events while optimizing patient medication persistence
Explain the patient’s and healthcare team’s responsibilities to optimize outcomes through ongoing education and communication to support adherence to oral cancer treatments
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST
Marilyn Johnston has nothing to disclose.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Ana Goffin, MPA, Program Manager for Med Learning Group has nothing to disclose.
Nina Oshiokpekhai MS, PharmD, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.

DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture Ms. Johnston may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: January 10, 2019

EXPIRATION DATE: January 10, 2020

VIEW ACTIVITY

 

This enduring activity is focused on use of biologics and targeted therapies in the management of Chronic Lymphocytic Leukemia (CLL).
Jan 10 2019 @ 2:45 pm – Jan 10 2020 @ 3:45 pm

Moving Beyond Chemotherapy in the Treatment of Patients with Chronic Lymphocytic Leukemia: Therapeutic and Management Considerations for Nursing

VIEW ACTIVITY

FACULTY
Leslie A. Andritsos, MD
Associate Professor of Medicine
University of New Mexico
Hematology
Albuquerque, NM

PROGRAM OVERVIEW
This enduring activity is focused on use of biologics and targeted therapies in the management of Chronic Lymphocytic Leukemia (CLL).

TARGET AUDIENCE
This initiative is designed to meet the educational needs of oncologists and oncology nurses involved in the management of patients with Chronic Lymphocytic Leukemia.

LEARNING OBJECTIVES
Upon completion of this enduring activity, participants will be able to:

Review the genomic and molecular underpinnings of CLL
Describe the prognostic criteria that can be used to risk-stratify patients with CLL in order to tailor targeted therapeutic approaches
Evaluate post-first-line treatment strategies for patients with relapsed/refractory CLL
Address barriers to effective management of CLL and provide effective strategies regarding patient communication with an emphasis on the unique role of oncology nurses
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of oncology patients.
Credits: 1 ANCC Contact Hour(s)

ACCREDITATION STATEMENT:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded a maximum of 1 contact hour(s) of continuing nursing education of RNs and APNs.

ONCC RECERTIFICATION POINTS
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Andritsos provides consulting services to AstraZeneca and has participated in an advisory board for AstraZeneca.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Ana Goffin, MPA, Program Manager for Med Learning Group has nothing to disclose.
Nina Oshiokpekhai MS, PharmD, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.

DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture Dr. Andritsos may mention the use of medications for both FDA-approved and non-approved indications.

DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: January 10, 2019

EXPIRATION DATE: January 10, 2020

VIEW ACTIVITY

 

This enduring activity is focused on use of biologics and targeted therapies in the management of Follicular Lymphoma (FL)
Jan 10 2019 @ 2:53 pm – Jan 10 2020 @ 3:53 pm

The Role of the Oncology Nurse in the Management of Follicular Lymphoma – Incorporating New Therapies and Applying Treatment Guidelines to the Clinical Practice Setting

VIEW ACTIVITY

FACULTY
Jigar Trivedi, MS, PharmD, BCOP
Pharmacist, Clinical Coordinator
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute
Charlotte, NC

PROGRAM OVERVIEW
This enduring activity is focused on use of biologics and targeted therapies in the management of Follicular Lymphoma (FL).

TARGET AUDIENCE
This initiative is designed to meet the educational needs of oncologists and oncology nurses involved in the management of patients with Follicular Lymphoma.

LEARNING OBJECTIVES
Upon completion of this enduring activity, participants will be able to:

Discuss the current guidelines for the 1st- and 2nd-line treatments of follicular lymphoma and their application to clinical practice
Review the clinical trials data for newly approved therapies in the first- and second-line treatment of follicular lymphoma
Describe the management of adverse effects associated with FL treatment based on a multidisciplinary team-based approach that includes shared decision making between health care providers and patients
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Med Learning Group designates enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of oncology patients.
Credits: 1 ANCC Contact Hour(s)

ACCREDITATION STATEMENT:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded a maximum of 1 contact hour(s) of continuing nursing education of RNs and APNs.

ONCC RECERTIFICATION POINTS
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Trivedi has received consulting fees from Astellas Pharma Inc., and Pharmacyclics

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Ana Goffin, MPA, Program Manager for Med Learning Group has nothing to disclose.
Nina Oshiokpekhai MS, PharmD, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.

DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture Dr. Trivedi may mention the use of medications for both FDA-approved and non-approved indications.

DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: January 10, 2019

EXPIRATION DATE: January 10, 2020

VIEW ACTIVITY

 

This enduring activity is focused on use of biologics and targeted therapies in the management of Head and Neck Cancer.
Jan 10 2019 @ 2:58 pm – Jan 10 2020 @ 3:58 pm

Leveraging the Immune System to treat Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

VIEW ACTIVITY

FACULTY
Ashish Chintakuntlawar, MD PhD
Associate Professor of Medicine
University of Chicago Medicine
Chicago, IL

PROGRAM OVERVIEW
This enduring activity is focused on use of biologics and targeted therapies in the management of Head and Neck Cancer.

TARGET AUDIENCE
This initiative is designed to meet the educational needs of oncologists and oncology nurses involved in the management of patients with Head and Neck Cancer.

LEARNING OBJECTIVES
Upon completion of this enduring activity, participants will be able to:

Describe the dysregulation of the immune system that supports the development of SCCHN
Review the mechanisms of action of immune-oncology therapies in patients with recurrent and metastatic SCCHN
Discuss clinical trial-derived efficacy and safety data for immuno-oncology agents for use in patients with recurrent or metastatic SCCHN
Explain how to recognize and manage check point inhibitor-associated immune-related adverse events in patients with SCCHN
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of oncology patients.
Credits: 1 ANCC Contact Hour(s)

ACCREDITATION STATEMENT:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded a maximum of 1 contact hour(s) of continuing nursing education of RNs and APNs.

ONCC RECERTIFICATION POINTS
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS
Faculty:
Dr. Chintakuntlawar has received funding (institutional) from Merck, AstraZeneca, Medimmune, Eisai Inovio, and Kura Oncology.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Ana Goffin, MPA, Program Manager for Med Learning Group has nothing to disclose.
Nina Oshiokpekhai MS, PharmD, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.

DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture Dr. Chintakuntlawar may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: January 10, 2019

EXPIRATION DATE: January 10, 2020

VIEW ACTIVITY

This enduring activity is focused on use of biologics and targeted therapies in the management of Acute Myeloid Leukemia (AML).
Jan 10 2019 @ 3:04 pm – Jan 10 2020 @ 4:04 pm

The Unique Role of the Oncology Nurse in the Management of Patients with Acute Myeloid Leukemia

VIEW ACTIVITY

FACULTY
Michael R. Grunwald, MD
Associate Director, Leukemia Division
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
Charlotte, NC

PROGRAM OVERVIEW
This enduring activity is focused on use of biologics and targeted therapies in the management of Acute Myeloid Leukemia (AML).

TARGET AUDIENCE
This initiative is designed to meet the educational needs of oncologists and oncology nurses involved in the management of patients with Acute Myeloid Leukemia.

LEARNING OBJECTIVES
Upon completion of this enduring activity, participants will be able to:

Review the pathophysiology of AML with an emphasis on targets for therapeutic intervention
Explain the mechanisms of action, efficacy, and safety of newly-approved and emerging targeted treatment options for AML
Explain the role of oncology nurses as members of AML patient health care teams
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of oncology patients.
Credits: 1 ANCC Contact Hour(s)
ACCREDITATION STATEMENT:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded a maximum of 1 contact hour(s) of continuing nursing education of RNs and APNs.

ONCC RECERTIFICATION POINTS
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Grunwald has received consulting fees for Incyte, Celgene, Pfizer, ARIAD, Cardinal Health, Amgen, Merck, and Agios. He has also received research funding from Amgen, Incyte, Genentech/Roche, Janssen, and Forma Therapeutics.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Ana Goffin, MPA, Program Manager for Med Learning Group has nothing to disclose.
Nina Oshiokpekhai MS, PharmD, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.

DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture Dr. Grunwald may mention the use of medications for both FDA-approved and non-approved indications.

DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: January 10, 2019

EXPIRATION DATE: January 10, 2020

VIEW ACTIVITY